22
Participants
Start Date
December 11, 2015
Primary Completion Date
October 31, 2019
Study Completion Date
October 14, 2021
KPT-330
KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
Rituximab
IV Rituximab 375 mg/m2 on D1
Etoposide
IV Etoposide 100 mg/m2 on D1-3
Carboplatin
IV Carboplatin AUC 5 on D2
Ifosfamide
IV Ifosfamide 5 g/m2 on D2
Dexamethasone
20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
Weill Cornell Medical College, New York
Collaborators (1)
Karyopharm Therapeutics Inc
INDUSTRY
The Leukemia and Lymphoma Society
OTHER
FDA Office of Orphan Products Development
FED
Weill Medical College of Cornell University
OTHER